.STUDY FEATURE.06 August 2024.
A sizable randomized regulated trial along with cisgender females highlights the problems of obedience to a daily oral preexposure treatment program as well as displays that twice-yearly shot of lenacapavir can easily sustain reliable HIV deterrence degrees over 6 months.